Cingulate Inc. 8-K

What Happened

• On June 2, 2026, Cingulate Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for CTx-1301 (dexmethylphenidate HCl) for the treatment of ADHD.
• The FDA's CRL identified specific Chemistry, Manufacturing, and Controls (CMC) information requests and did not raise current concerns about the clinical safety or efficacy of CTx-1301. Cingulate said it expects a prompt resubmission of the remaining requested information.

Key Details

• Date of announcement: June 2, 2026.
• Product: CTx-1301 (dexmethylphenidate HCl) — NDA for ADHD.
• Regulatory action: FDA issued a CRL focused on CMC items; no clinical safety/efficacy issues were cited.
• Company response: Plans a prompt resubmission to address the FDA's CMC requests; press release filed as Exhibit 99.1.

Why It Matters

• A CRL means the FDA is not approving the NDA as submitted, which can delay the drug’s approval timeline and potential future revenue.
• The CRL being limited to CMC matters (with no current clinical safety/efficacy concerns) is relatively favorable because it suggests issues may be resolved without new clinical trials, lowering the chance of major clinical setbacks.
• Investors should watch for updates on the timing and completeness of Cingulate’s resubmission and any revised regulatory timeline or additional disclosure about the scope and timeline of the CMC work.